CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020.
A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
弥漫性大B细胞淋巴瘤(DLBCL)是发病率最高的非霍奇金淋巴瘤(NHL)亚型,约占NHL病例的三分之一。鉴于DLBCL领域已积累大量科学文献,本研究采用文献计量学方法,对本世纪以来DLBCL研究进行全面综述。从Web of Science数据库严格检索并导出2001至2020年发表的10,869篇文献,分析其时间和地域分布,以及相关国家、机构、期刊和作者的产出情况,并通过关键词共现进行深入内容分析。发文量最多的国家是美国,共2,344篇(21.6%),且与其他国家合作最频繁。相比之下,中国多年来发文增长显著,并在最近5年发文量居首。德克萨斯大学系统是发文量最多的机构(占4.99%);Leukemia & Lymphoma是该领域发文最多的期刊,共发表588篇。各学者之间扎实而紧密的合作在四个五年期内日益频繁。过去20年合作最频繁的研究团队来自加拿大不列颠哥伦比亚癌症中心及研究中心的Gascoyne RD团队。比较各五年期文章引用和关键词共现情况,以及20年来关键词聚类变化后发现,DLBCL的分期、评估、预后和治疗始终是研究热点。关键词共现的演变还显示新的研究聚类不断出现,例如铁死亡机制对DLBCL的影响、DLBCL免疫治疗及PD-L1、PD-L2和CAR-T 疗法均受到学界日益关注。
本研究概述DLBCL研究的关键特征,并全面展示该领域的现状及演变。
Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin lymphoma (NHL) with the highest incidence, accounting for approximately one-third of NHL cases. Given the accumulated scientific publications related to the DLBCL domain, this study aimed to provide a comprehensive review of DLBCL studies from this millennium using the bibliometric method. With a strict retrieval strategy applied in the Web of Science database, a total of 10,869 publications from 2001 to 2020 were obtained and exported. The temporal and geographical distribution of these publications and the performance of contributing countries, institutions, journals, and authors corresponding to these documents were investigated, as well as an in-depth content analysis through keyword co-occurrence.
With regard to the most productive countries, the United States ranks first with 2344 (21. 6%) publications and shows the most frequent collaborations with other countries. By contrast, China has demonstrated remarkable performance in the growth rate of publications over the years, and it ranks first in the number of publications in the last five years.
The University of Texas System is the institution with the highest number of published articles (4. 99%). Leukemia Lymphoma is the journal with the highest number of publications in this field which contributed 588 articles. Solid and close collaborations between scholars are becoming more frequent over the four five-year periods.
Overall, the highest cooperation frequency in the last two decades happens to Gascoyne RD at the British Columbia Cancer Agency and British Columbia Cancer Research Center in Canada. By comparing the article citation and keyword co-occurrence in each five-year period, as well as the changes in keyword clusters over two decades, we conclude that the stage, evaluation, prognosis, and treatment of DLBCL have always been the research hotspots in this field.
Meanwhile, the evolution of keyword co-occurrence over the years demonstrates that new clusters appear. For instance, the effect of ferroptosis mechanism in DLBCL, immunotherapy for DLBCL, and PDL-1, PDL-2, and CAR-T therapy have drawn increasing attention from academia.
Our research highlights the key characteristics of DLBCL research and provides comprehensive insights into the research status and evolutions in this field.
MEMBER ACCOUNT
登录成功会直接打开下一页。